We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is AstraZeneca's Oncology Portfolio Positioned for Continued Growth?
Read MoreHide Full Article
Key Takeaways
AstraZeneca's oncology sales rose 15% to $14.1 billion in H1 2026, led by key cancer drugs.
Truqap and Datroway are expanding across cancer settings, adding momentum beyond established blockbusters.
Etcamah and late-stage candidates could provide further growth through new indications and therapies.
Over the past decade, AstraZeneca (AZN - Free Report) has built a broad oncology franchise spanning multiple cancer types, including lung, breast, blood, gastrointestinal and genitourinary cancers. The segment contributes roughly 46% of total revenues and is the company’s largest therapeutic area.
AstraZeneca’s oncology sales were $14.1 billion in the first half of 2026, up 15% at constant exchange rate (CER). The strong oncology performance was driven by robust demand for drugs like Tagrisso, Lynparza, Imfinzi, Calquence and Enhertu (in partnership with Daiichi Sankyo). AstraZeneca has a profit-sharing deal with Merck (MRK - Free Report) . (MRK - Free Report) for Lynparza.
AZN Looks Beyond Its Established Oncology Blockbusters
Interestingly, AstraZeneca’s oncology growth story is increasingly shifting from a few established blockbusters toward multiple newer products and label expansions.
Key new cancer drugs in AstraZeneca’s portfolio are Truqap for HR-positive, HER2-negative (HR+ HER2-) breast cancer and Datroway, a TROP2-directed antibody drug conjugate or ADC co-developed with partner Daiichi. Datroway is approved for the treatment of HR-positive, HER2-negative breast cancer, unresectable or metastatic triple-negative breast cancer in patients who are not candidates for PD-1/PD-L1 inhibitor therapy, and EGFR-mutated locally advanced or metastatic NSCLC.
The majority of Truqap’sgrowth comes from ex-U.S. markets, with the U.S. opportunity at its peak in the breast cancer indication. However, AstraZeneca is expected to soon launch Truqap for patients with PTEN-deficient metastatic hormone-sensitive prostate cancer following the June approval based on CAPItello-281 study data.
Datroway is seeing strong launch uptake trends. AstraZeneca is evaluating Datroway in multiple breast and lung cancer settings, including combinations with Imfinzi, pembrolizumab, rilvegostomig and Tagrisso.
Another new cancer drug, Etcamah (camizestrant), a next-generation oral SERD, was approved for first-line advanced ER-positive, HER2-negative advanced breast cancer in the EU in July 2026, while it is under review in the United States.
Pipeline and Label Expansions Support AZN’s Long-Term Growth
AstraZeneca is also working to strengthen its oncology product portfolio through label expansions of existing products and to advance its oncology pipeline candidates.
AstraZeneca arguably possesses one of the deepest late-stage oncology pipelines in the industry. Important late-stage oncology candidates in AstraZeneca’s pipeline are volrustomig (a next-generation bispecific immunotherapy for lung, colorectal, cervical, head and neck and esophageal cancers), sonesitatug vedotin (a novel ADC targeting CLDN18.2 for advanced or metastatic gastric or GEJ adenocarcinoma), surovatamig (a CD19 CD3 T-cell engager for haematologic malignancies) and rilvegostomig (a next-generation immunotherapy for NSCLC and gastrointestinal cancers).
Conclusion
Looking ahead, AstraZeneca’s oncology business should remain a key growth driver, supported by continued demand for Tagrisso, Imfinzi and Enhertu, along with the expansion of newer products such as Datroway, Truqap and Etcamah. Growthfrom new indications and combination therapies should help offset the gradual maturation of some established medicines. Further out, pipeline candidates such as rilvegostomig, volrustomig and several ADCs could provide additional growth opportunities and help AstraZeneca sustain the momentum of its oncology franchise.
Competition in the Oncology Space
Other large players in the oncology space are Pfizer (PFE - Free Report) , Merck, J&J (JNJ - Free Report) and Bristol-Myers.
For Pfizer, oncology sales comprise around 27% of its total revenues. Its oncology revenues grew 5% in the first half of 2026, driven by drugs like Xtandi, Lorbrena, the Braftovi-Mektovi combination and Padcev. Pfizer considers Padcev to be a potential growth driver in the oncology segment and plans to invest in this asset.
Oncology accounts for nearly 29% of J&J’s total revenues. In the first half of 2026, oncology revenues increased 16.9% to $14.4 billion on an operational basis, fueled by continued momentum for Darzalex and Erleada, although weaker demand for Imbruvica partially offset these gains. J&J’s new cancer drugs, Carvykti, Tecvayli, Talvey and Rybrevant/Lazcluze are contributing significantly to top-line growth driven by market share gains.
Merck’s key oncology medicines are the PD-L1 inhibitor Keytruda and the PARP inhibitor Lynparza, which it markets in partnership with AstraZeneca. Keytruda, approved for several types of cancer, alone accounts for more than 55% of the company’s pharmaceutical sales. Keytruda recorded sales of $15.8 billion in the first half of 2026, up 4% year over year.
AZN’s Price Performance, Valuation and Estimates
AZN stock has declined 9.4% so far this year against an appreciation of 13.2% for the industry.
Image Source: Zacks Investment Research
From a valuation standpoint, AstraZeneca is reasonably valued. Going by the price/earnings ratio, the company’s shares currently trade at 16.27 forward earnings, lower than 18.24 for the industry. The stock is also trading lower than its 5-year mean of 17.30.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2026 earnings has declined from $10.22 per share to $9.37 per share over the past 60 days. For 2027, earnings estimates have declined from $11.42 per share to $10.55 per share over the same timeframe.
View the Zacks #1 Rank List
Image: Bigstock
Is AstraZeneca's Oncology Portfolio Positioned for Continued Growth?
Key Takeaways
Over the past decade, AstraZeneca (AZN - Free Report) has built a broad oncology franchise spanning multiple cancer types, including lung, breast, blood, gastrointestinal and genitourinary cancers. The segment contributes roughly 46% of total revenues and is the company’s largest therapeutic area.
AstraZeneca’s oncology sales were $14.1 billion in the first half of 2026, up 15% at constant exchange rate (CER). The strong oncology performance was driven by robust demand for drugs like Tagrisso, Lynparza, Imfinzi, Calquence and Enhertu (in partnership with Daiichi Sankyo). AstraZeneca has a profit-sharing deal with Merck (MRK - Free Report) .
(MRK - Free Report) for Lynparza.
AZN Looks Beyond Its Established Oncology Blockbusters
Interestingly, AstraZeneca’s oncology growth story is increasingly shifting from a few established blockbusters toward multiple newer products and label expansions.
Key new cancer drugs in AstraZeneca’s portfolio are Truqap for HR-positive, HER2-negative (HR+ HER2-) breast cancer and Datroway, a TROP2-directed antibody drug conjugate or ADC co-developed with partner Daiichi. Datroway is approved for the treatment of HR-positive, HER2-negative breast cancer, unresectable or metastatic triple-negative breast cancer in patients who are not candidates for PD-1/PD-L1 inhibitor therapy, and EGFR-mutated locally advanced or metastatic NSCLC.
The majority of Truqap’sgrowth comes from ex-U.S. markets, with the U.S. opportunity at its peak in the breast cancer indication. However, AstraZeneca is expected to soon launch Truqap for patients with PTEN-deficient metastatic hormone-sensitive prostate cancer following the June approval based on CAPItello-281 study data.
Datroway is seeing strong launch uptake trends. AstraZeneca is evaluating Datroway in multiple breast and lung cancer settings, including combinations with Imfinzi, pembrolizumab, rilvegostomig and Tagrisso.
Another new cancer drug, Etcamah (camizestrant), a next-generation oral SERD, was approved for first-line advanced ER-positive, HER2-negative advanced breast cancer in the EU in July 2026, while it is under review in the United States.
Pipeline and Label Expansions Support AZN’s Long-Term Growth
AstraZeneca is also working to strengthen its oncology product portfolio through label expansions of existing products and to advance its oncology pipeline candidates.
AstraZeneca arguably possesses one of the deepest late-stage oncology pipelines in the industry. Important late-stage oncology candidates in AstraZeneca’s pipeline are volrustomig (a next-generation bispecific immunotherapy for lung, colorectal, cervical, head and neck and esophageal cancers), sonesitatug vedotin (a novel ADC targeting CLDN18.2 for advanced or metastatic gastric or GEJ adenocarcinoma), surovatamig (a CD19 CD3 T-cell engager for haematologic malignancies) and rilvegostomig (a next-generation immunotherapy for NSCLC and gastrointestinal cancers).
Conclusion
Looking ahead, AstraZeneca’s oncology business should remain a key growth driver, supported by continued demand for Tagrisso, Imfinzi and Enhertu, along with the expansion of newer products such as Datroway, Truqap and Etcamah. Growthfrom new indications and combination therapies should help offset the gradual maturation of some established medicines. Further out, pipeline candidates such as rilvegostomig, volrustomig and several ADCs could provide additional growth opportunities and help AstraZeneca sustain the momentum of its oncology franchise.
Competition in the Oncology Space
Other large players in the oncology space are Pfizer (PFE - Free Report) , Merck, J&J (JNJ - Free Report) and Bristol-Myers.
For Pfizer, oncology sales comprise around 27% of its total revenues. Its oncology revenues grew 5% in the first half of 2026, driven by drugs like Xtandi, Lorbrena, the Braftovi-Mektovi combination and Padcev. Pfizer considers Padcev to be a potential growth driver in the oncology segment and plans to invest in this asset.
Oncology accounts for nearly 29% of J&J’s total revenues. In the first half of 2026, oncology revenues increased 16.9% to $14.4 billion on an operational basis, fueled by continued momentum for Darzalex and Erleada, although weaker demand for Imbruvica partially offset these gains. J&J’s new cancer drugs, Carvykti, Tecvayli, Talvey and Rybrevant/Lazcluze are contributing significantly to top-line growth driven by market share gains.
Merck’s key oncology medicines are the PD-L1 inhibitor Keytruda and the PARP inhibitor Lynparza, which it markets in partnership with AstraZeneca. Keytruda, approved for several types of cancer, alone accounts for more than 55% of the company’s pharmaceutical sales. Keytruda recorded sales of $15.8 billion in the first half of 2026, up 4% year over year.
AZN’s Price Performance, Valuation and Estimates
AZN stock has declined 9.4% so far this year against an appreciation of 13.2% for the industry.
From a valuation standpoint, AstraZeneca is reasonably valued. Going by the price/earnings ratio, the company’s shares currently trade at 16.27 forward earnings, lower than 18.24 for the industry. The stock is also trading lower than its 5-year mean of 17.30.
The Zacks Consensus Estimate for 2026 earnings has declined from $10.22 per share to $9.37 per share over the past 60 days. For 2027, earnings estimates have declined from $11.42 per share to $10.55 per share over the same timeframe.
AstraZeneca has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.